Investors Purchase High Volume of CytomX Therapeutics Call Options (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Free Report) was the target of some unusual options trading on Wednesday. Stock traders acquired 16,565 call options on the stock. This is an increase of 7,197% compared to the average volume of 227 call options.

Insider Activity at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the sale, the chief executive officer now directly owns 524,481 shares of the company’s stock, valued at $1,096,165.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 35,024 shares of company stock valued at $73,200 over the last ninety days. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AlphaMark Advisors LLC lifted its stake in shares of CytomX Therapeutics by 119.8% in the fourth quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 12,635 shares during the period. Congress Park Capital LLC increased its holdings in CytomX Therapeutics by 112.8% in the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 126,850 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in CytomX Therapeutics by 737.4% in the third quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 234,970 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $4.50 on Friday. The stock’s 50 day moving average is $2.20 and its 200 day moving average is $1.69. The firm has a market cap of $304.79 million, a P/E ratio of -224.89 and a beta of 1.09. CytomX Therapeutics has a one year low of $1.04 and a one year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMXGet Free Report) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to the consensus estimate of $23.36 million. Equities analysts anticipate that CytomX Therapeutics will post -0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on CTMX. StockNews.com lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. BMO Capital Markets reissued a “market perform” rating and set a $3.25 price target on shares of CytomX Therapeutics in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Monday, April 22nd.

Check Out Our Latest Research Report on CTMX

About CytomX Therapeutics

(Get Free Report)

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

See Also

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.